Physician profile
Norman Heching
NPI 1366471260
$1,739.17
in general payments reported to CMS, 2019-2025
30 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $45.48 · 2024: $369 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,739.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $352.57 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Incyte Corporation | $212.65 | 2024-2025 | Jakafi, Niktimvo, Monjuvi |
| Merck Sharp & Dohme LLC | $156.41 | 2024-2025 | Keytruda, Reblozyl, Welireg |
| Astrazeneca Pharmaceuticals LP | $121.88 | 2024-2025 | Calquence, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $104.44 | 2024-2025 | Fruzaqla, Iclusig |
| Exelixis INC. | $74.72 | 2024-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $69.45 | 2024-2025 | Ojjaara, Blenrep |
| Bayer Healthcare Pharmaceuticals INC. | $68.50 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $67.26 | 2025 | Opdivo |
| Celgene Corporation | $57.38 | 2025 | Reblozyl, Opdualag |
| Genmab U.S., INC. | $39.57 | 2025 | Epkinly, Tivdak |
| Adc Therapeutics America, INC. | $37.90 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $37.05 | 2023-2025 | Libtayo |
| Array Biopharma INC | $35.66 | 2024-2025 | Tukysa, Braftovi, Mektovi |
| Eisai INC. | $35.40 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $26.33 | 2025 | |
| Kyowa Kirin, INC. | $23.83 | 2025 | |
| Emd Serono, INC. | $22.56 | 2025 | |
| Alexion Pharmaceuticals, INC. | $22.08 | 2025 | Ultomiris |
| Genentech USA, INC. | $18.63 | 2025 | Polivy, Tecentriq Hybreza, Columvi |
| Abbvie INC. | $18.55 | 2024 | |
| Janssen Biotech, INC. | $17.91 | 2025 | Carvykti |
| Tersera Therapeutics LLC | $17.18 | 2025 | Quzyttir |
| Syndax Pharmaceuticals, INC. | $15.99 | 2025 | Revuforj |
| Beone Medicines USA, INC. | $15.45 | 2025 | Tevimbra |
| Acrotech Biopharma INC. | $14.42 | 2025 | Beleodaq |
| Sobi, INC | $14.14 | 2024 | |
| Pfizer INC. | $14.06 | 2025 | |
| Geron Corporation | $13.85 | 2025 | Rytelo |
| Novocure INC. | $13.35 | 2024 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Heching listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.